|
Acromegaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
Congestive heart failure worsening with octreotide in acromegalic patient.
|
1682667 |
1991 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinical acromegaly is characterized by dysregulation of somatotroph GH secretion in the presence of high circulating serum IGF-I levels.
|
7704960 |
1995 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We report here the case of a 46-yr-old woman with a large pituitary macroadenoma, slightly elevated serum GH levels, high serum insulin-like growth factor-I levels, and abnormal GH dynamics, but no acromegaly.
|
8432778 |
1993 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that this association (i.e.Beckwith-Wiedemann syndrome and acromegaly) is independent, and point out that IGF I and II might be very high in the Beckwith-Wiedemann fetus.
|
8838774 |
1996 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Screening of 26 members revealed the possible diagnosis of PHP in 1 family member in generation II and possible early acromegaly in 2 members of generation III with elevated serum concentrations of insulin-like growth factor I and insulin-like growth factor-binding protein-3 but normal patterns of pulsatile GH release.
|
9024241 |
1997 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
Twenty-four hour melatonin pattern in acromegaly: effect of acute octreotide administration.
|
9186818 |
1997 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
|
9348175 |
1997 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trials in patients with acromegaly show GHR blockade to be an exciting new mode of therapy for this condition, and pegvisomant may have a therapeutic role in diseases, such as diabetes and malignancy, in which abnormalities of the GH/IGF-I axis have been observed.
|
12372843 |
2002 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum GH and IGF-I levels were higher in patients with untreated acromegaly than in those with acromegaly in remission or controls (P = 0.003 and P = 0.002, respectively) The expression of PPARgamma mRNA (mean +/- SE) was 1) mucosa outside polyps, 24,188 +/- 3,254 transcripts in the controls, 22,432 +/- 2,006 transcripts in acromegaly in remission, and 1,952 +/- 342 transcripts in untreated acromegaly (P < 0.0001 vs. controls and acromegaly in remission); and 2) polyps mucosa, 1,554 +/- 236 transcripts in the controls, 1,112 +/- 143 in acromegaly in remission, and 1,570 +/- 251 in untreated acromegaly (P = NS among polyps groups and mucosa outside polyps of untreated acromegaly; P < 0.0001 vs. mucosa outside polyps of controls and acromegaly in remission).
|
12915690 |
2003 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest a role for SSTR5 t-461c and c1004t alleles in influencing GH and IGF-I levels in patients with acromegaly, whereas SSTR2 and SSTR5 variants seem to have a minor role in determining the responsiveness to somatostatin analogs.
|
15914528 |
2005 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, a GH-receptor blocking agent, pegvisomant, was licensed for use in acromegaly and appears to normalise IGF-1 in almost all patients.
|
16262568 |
2005 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The pathogenesis of increased blood pressure (BP) in acromegaly is unclear, and the role of IGF-I levels and the renin-angiotensin-aldosterone system (RAAS) in this disease remains controversial.
|
17003099 |
2006 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to test whether the relationship between GH and insulin-like growth factor-1 (IGF-1) concentrations is influenced by the GHR genotype in patients with acromegaly.
|
17573420 |
2007 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As far as polymorphic variants of SST genes are concerned, a possible role of SST5 C1004T and T-461C alleles in influencing GH and IGF-I levels in patients with acromegaly has been proposed.
|
17913341 |
2008 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
LHGDN |
These observations suggest that appropriate levels of IGF-I have beneficial cardioprotective effects after surgery in patients with acromegaly.
|
18037753 |
2007 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
Excess GH and IGF-I in acromegaly are associated with reduced life expectancy due to cardiovascular complications.
|
18381583 |
2008 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
CTD_human |
Our findings provide the first evidence that GH, in concert with IGF-I, stimulates ENaC-mediated sodium transport in the late distal nephron, accounting for the pathogenesis of sodium retention in acromegaly.
|
18388193 |
2008 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to evaluate the impact of GH receptor (GHR) polymorphism on the biochemical assessment of the treatment of acromegaly and on prevalence of discordant levels of GH and IGF-I.
|
19336510 |
2009 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we examined whether the exon 3-deleted (d3) GH receptor (GHR) variant, which has been linked to increased responsiveness to GH treatment in short children, influences the GH/IGF1 relationship in patients with acromegaly.
|
19439509 |
2009 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a disease of exaggerated somatic growth and distorted proportion arising from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
20234189 |
2010 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible influences of d3GHR on the GH/IGF-I relationship and metabolic parameters in acromegaly.
|
20447065 |
2010 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly.
|
20920870 |
2010 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that increased MN frequency in the lymphocytes of patients with acromegaly may reflect genomic instability and this increased MN frequency may be associated with elevated levels of circulating growth hormone and IGF-1.
|
21550080 |
2011 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
|
22364960 |
2012 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a pathological condition associated with excess growth hormone (GH) and insulin-like growth factor-I (IGF-I) and a high prevalence of diabetes, hypertension, atherosclerosis, and heart failure; resulting in premature death.
|
22370764 |
2012 |